News

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

Earlier this week, SELLAS Life Sciences Group highlighted that its REGAL Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia has reached 78 of the 80 required overall survival events, bringing the pivotal data readout within sight. Investor interest has also been shaped by amended executive employment agreements that include change-of-control benefits, feeding speculation about potential corporate developments alongside the awaited GPS results. With the REGAL Phase 3 GPS data...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet the stock currently screens as expensive on broad valuation checks. This sets up a clear tension between recent share price strength and what the fundamentals suggest about value. Over 3 years, the stock has returned close to 7x, which puts extra focus on whether that gain is supported by fundamentals or mainly by sentiment. Expectations for strong revenue and earnings growth, combined with a sizeable shelf registration...

SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid leukemia approaches the required events for an overall survival readout, a key catalyst for the stock. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.19, SELLAS Life Sciences Group has seen a 69.97% 1 month share price return and a 203.22% year to date share price return. The 1 year total shareholder return is very large, signaling that...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm […]

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

SELLAS Life Sciences Group stock has surged over the past three years, yet its low overall value score and rich market multiples leave investors weighing a strong price run against signals that the shares may already be pricing in a lot of good news. A roughly 8.5x return over 3 years places SELLAS Life Sciences Group among the stronger movers in biotech, which can heighten the risk that expectations get ahead of fundamentals. Anticipation around the Phase 3 REGAL AML trial readout and...

In recent days, SELLAS Life Sciences Group updated employment and severance agreements for key executives while its Phase 3 REGAL trial in acute myeloid leukemia neared final overall survival analysis, with 78 of 80 required events reached. These enhanced change‑of‑control terms, combined with the late‑stage status of galinpepimut‑S and early‑stage CDK9 inhibitor SLS009, have intensified market discussion about potential acquisition interest and the company’s long‑term oncology...

We just covered the 10 Stocks That Will 10X According to Social Media. Sellas Life Sciences (NASDAQ:SLS) ranks #10 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 13 Sellas Life Sciences (NASDAQ:SLS) is one of the top favorite stocks social media believes can 10x. It is a biotech […]

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated: Oh, this life science company that is, look, okay, so this is […]

In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and prior Phase 2 results while the Phase 3 REGAL trial of GPS in AML moved to within two events of a topline readout. Investor interest was further amplified when CNBC’s Jim Cramer described SELLAS as “a great spec,” underscoring how imminent REGAL data and the progress of second AML candidate SLS009 are shaping perceptions of the company’s pipeline. We’ll now examine how the approaching REGAL...

Earlier in 2026, SELLAS Life Sciences Group, Inc. reported a US$8.41 million net loss for the first quarter but narrowed its basic loss per share to US$0.05, while confirming that its pivotal Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis. At the same time, SELLAS advanced its SLS009 program into an 80‑patient Phase 2 trial for newly diagnosed, high‑risk acute myeloid leukemia and secured additional funding flexibility through a...

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline. CEO Angelos Stergiou said the company continued advancing its clinical programs during the quarter while preparing for the anticipated data readout from its pivotal Phase 3 REGAL study. SELLAS will release the upcoming data after the study reaches its pre-specified 80th event threshold — a major milestone for the

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]

Assessing recent moves in SELLAS Life Sciences Group (SLS) SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 months and year that stand out against its mixed multi year track record. Over the past month the stock shows a gain, alongside a much stronger move in the past 3 months and a very large 1 year total return, while 5 year performance remains negative. That mix often prompts investors to revisit the story behind the...

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...